Phase 1/2 RESTORE-MASH trial will evaluate safety, pharmacokinetics, and pharmacodynamics of TGM-312 in healthy volunteers and MASH ...
Grand Cayman, Cayman Island, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage, oncology-focused biotechnology company, today announced that ...
BOSTON--(BUSINESS WIRE)--Atalanta Therapeutics, a biotechnology company pioneering new treatment options for neurodegenerative diseases, launched today with a Series A financing exclusively by F-Prime ...
Building sustainable product engine for innovative RNAi therapeutics to make a significant impact for patients across multiple disease indications, with first program expected to enter clinical ...
− Presents Pre-clinical Data with IKARIA Platform Demonstrating Potential to Achieve Over 90% Target Knockdown with an Annual Dosing Regimen – “At OTS this year we are pleased to share research ...
– Qfitlia Becomes the Sixth Alnylam-Discovered RNAi Therapeutic Approved by U.S. FDA and First and Only to Treat Hemophilia A or B With or Without Inhibitors – Qfitlia is the sixth Alnylam-discovered ...
Biogen Inc. and City Therapeutics, Inc. announced a strategic collaboration to develop novel RNA interference (RNAi) therapies targeting central nervous system diseases. City Therapeutics will utilize ...
As RNA therapeutics evolve far beyond their vaccine origins, a new generation of scientists and manufacturers is rethinking how to produce these complex medicines safely, efficiently, and at scale.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results